Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine

By Safari Dodi   Marradi Marco   Chiodo Fabrizio   Th Dekker Huberta A   Shan Yulong   Adamo Roberto   Oscarson Stefan   Rijkers Ger T   Lahmann Martina   Kamerling Johannis P   Penadés Soledad   Snippe Harm  

Nanomedicine, Vol. 7, Iss. 5, 2012-05 ,pp. : 651-662

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

By Bergman Annika   Hjelmgren Jonas   Ortqvist Åke   Wisløff Torbjørn   Sønbø Kristiansen Ivar   Diaz Hogberg Liselotte   M-S Persson Kristina   Persson Ulf  

Scandinavian Journal of Infectious Diseases, Vol. 40, Iss. 9, 2008-01 ,pp. : 721-729

Informa Healthcare

Access to resources Recommend Favorite

Economic impact of 13‐valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 20, Iss. 4, 2014-08 ,pp. : 333-341

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure

By Novak Daniel   Lundgren Anna   Westphal Susanne   Valdimarsson Sindri   Olsson Martin L.   Trollfors Birger  

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 5, 2013-05 ,pp. : 411-414

Informa Healthcare

Access to resources Recommend Favorite

Antibiotic susceptibility, serotype distribution and vaccine coverage of nasopharyngeal and oropharyngeal Streptococcus pneumoniae in a day-care centre in St. Petersburg, Russia

By Katz Anna   Leibovitz Eugene   Timchenko Viktor   Greenberg David   Porat Nurit   Peled Nehama   Dagan Ron   Ossipov Iuri  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 4, 2007-01 ,pp. : 293-298

Informa Healthcare

Access to resources Recommend Favorite